1Bahn RS,Houfolder AE. Pathogenesis of Graves ' ophthalmopathy[J].New England Journal of Medicine,1993,(20):1468-1475.
2Wiersinga WM,Bartalena L. Epidemiology and prevention of Graves'ophthalmopathy[J].Thyroid:Official Journal of the American Thyroid Association,2002,(10):855-860.
3Garrity JA,Bahn RS. Perspective pathogenesis of graves ophthalmopathy:implications for prediction,prevention,and treatment[J].American Journal of Ophthalmology,2006,(01):147-153.
4Gopinath B,Ma G,Wall JR. Eye signs and serum eye muscle and collagen ⅩⅢ antibodies in patients with transient and progressive thyroiditis[J].Thyroid:Official Journal of the American Thyroid Association,2007,(11):1123-1129.
5Ai Yoshihara,Jaeduk Yoshimura Noh,Ayako Nakachi. Severe thyroid-associated orbitopathy in Hashimoto's thyroiditis.Report of 2 cases[J].Endocrine Journal,2011,(05):343-348.
6Burch HB,Wartofsky B. Graves' ophthalmopathy:current concepts regarding pathogenesis and management[J].Endocrine Reviews,1993,(06):747-793.
7Matthews DC,Syed AA. The role of TSH receptor antibodies in the management of Graves' disease[J].European Journal of Internal Medicine,2011,(03):213-216.
8Bartalean L. Graves'ophthalmopathy:search for shared autoantigen (s)continues[J].Journal of Endocrinological Investigation,2005,(05):396-397.
9Agretti P,De Marco G,De Servi M. Evidence for protein and mRNA TSHr expression in fibroblasts from patients with thymid-associated ophthalmopathy (TAO) after adipocytic differentiation[J].Eur J Endocrionl,2005,(05):777-784.
10Bahn RS. Graves'ophthalmopathy[J].New England Journal of Medicine,2010,(08):726-738.
